Rothschild & Co has initiated coverage on Bruker Corp (BRKR) with a Buy rating, marking the firm's first assessment of the company’s investment potential. This decision reflects their research into Bruker's position within the life sciences tools and services industry, as well as its growth prospects.
Bruker Corp, headquartered in Billerica, Massachusetts, specializes in developing, manufacturing, and distributing high-performance scientific instruments and analytical solutions. The company employs 11,396 people and operates several segments, including Bruker Scientific Instruments, which focuses on magnetic resonance technology, and Bruker Energy & Supercon Technologies, which develops materials for renewable energy and healthcare applications.
As of November 20, 2025, Bruker shares are priced at $45.75, with a market capitalization of $6.9 billion. The company has reported a trailing twelve months (TTM) earnings per share (EPS) of -0.14 and boasts a substantial dividend yield of 46.1%.
Looking ahead, Bruker is set to announce earnings on August 3, 2026, with an EPS estimate of $0.44 and projected revenues of $837.8 million. Recent earnings performance has shown variability, with Q3 2025 EPS at $0.45, surpassing estimates by 31.7%.
Analyst consensus currently indicates 6 Strong Buy, 6 Buy, 8 Hold, 1 Sell, and no Strong Sell ratings, suggesting a generally favorable outlook for the company. Analyst ratings are subject to change as new information becomes available, and they should be one of several factors considered in investment decisions.
This update provides insight into how analysts view Bruker Corp's potential in the competitive landscape of life sciences tools.